×
About 31,945 results

ALLMedicine™ Renal Cell Carcinoma Center

Research & Reviews  10,263 results

A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
https://clinicaltrials.gov/ct2/show/NCT04923178

Aug 12th, 2022 - Background: Rare histological variants of the GU tract include bladder/urachal adenocarcinoma, squamous cell carcinoma, and small cell carcinoma; variants of urothelial carcinoma including plasmacytoid, sarcomatoid; renal tumors including sarcomat...

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT02819596

Aug 12th, 2022 - This study is being carried out to see if the drugs MEDI4736, Savolitinib and Tremelimumab can be used alone or in combination to reduce the size of tumours in patients with kidney cancer. The drugs being tested in this study have an anti-tumour e...

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
https://clinicaltrials.gov/ct2/show/NCT05239728

Aug 12th, 2022 - The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) ...

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT05155033

Aug 12th, 2022 - Background: High-dose interleukin-2 was approved by the FDA for the treatment of metastatic melanoma and renal cell carcinoma, with overall response rates of 15-16%. Complete regression of disease was seen in 6-7% of participants with many long-te...

Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
https://clinicaltrials.gov/ct2/show/NCT00050752

Aug 12th, 2022 - Background: Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a rare autosomal dominantly inherited disorder which confers susceptibility to develop cutaneous and uterine leiomyomas and renal cell carcinoma. HLRCC is caused by mutations i...

see more →

Guidelines  23 results

ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clini...
https://doi.org/10.1016/j.jacr.2022.02.015
Journal of the American College of Radiology : JACR; , Purysko AS et. al.

May 14th, 2022 - Renal cell carcinoma (RCC) accounts for most malignant renal tumors and is considered the most lethal of all urologic cancers. For follow-up of patients with treated or untreated RCC and those with neoplasms suspected to represent RCC, radiologic ...

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2022.0001
Journal of the National Comprehensive Cancer Network : JN... Motzer RJ, Jonasch E et. al.

Jan 7th, 2022 - The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor hist...

Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523177/
Journal of Kidney Cancer and VHL; Lin J

Oct 13th, 2021 - Advance diagnostic and treatment modalities have improved outcomes for renal cell carcinoma (RCC) patients, but the prognosis for those with metastatic disease (mRCC) remains poor. As given metastatic distribution is critical in guiding treatment ...

Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing
https://pubmed.ncbi.nlm.nih.gov/34654685/
European Urology Oncology; Truong H

Oct 12th, 2021 - Despite guidelines recommending genetic counseling for patients with early-onset renal cell carcinoma (RCC), studies interrogating the spectrum of germline mutations and clinical associations in patients with early-onset RCC are lacking.

ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and ...
https://doi.org/10.1016/j.annonc.2021.09.014
Annals of Oncology : Official Journal of the European Soc... Powles T, Albiges L et. al.

Oct 2nd, 2021 - ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma.|2021|Powles T,Albiges L,Bex A,Grünwald V,Porta C,|drug therapy,drug therapy,

see more →

Drugs  47 results see all →

Clinicaltrials.gov  1,055 results

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT02819596

Aug 12th, 2022 - This study is being carried out to see if the drugs MEDI4736, Savolitinib and Tremelimumab can be used alone or in combination to reduce the size of tumours in patients with kidney cancer. The drugs being tested in this study have an anti-tumour e...

PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT03108066

Aug 12th, 2022 - This open-label Phase 2 study will evaluate the efficacy, safety, PK, and PD of PT2385 in patients with VHL disease who have at least 1 measurable VHL disease-associated ccRCC tumor (as defined by RECIST 1.1). PT2385 will be administered orally an...

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab an...
https://clinicaltrials.gov/ct2/show/NCT04736706

Aug 12th, 2022 - The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced ...

A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
https://clinicaltrials.gov/ct2/show/NCT04923178

Aug 12th, 2022 - Background: Rare histological variants of the GU tract include bladder/urachal adenocarcinoma, squamous cell carcinoma, and small cell carcinoma; variants of urothelial carcinoma including plasmacytoid, sarcomatoid; renal tumors including sarcomat...

Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
https://clinicaltrials.gov/ct2/show/NCT00050752

Aug 12th, 2022 - Background: Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a rare autosomal dominantly inherited disorder which confers susceptibility to develop cutaneous and uterine leiomyomas and renal cell carcinoma. HLRCC is caused by mutations i...

see more →

News  1,386 results

Treatment Combo Shows 'Clinical Benefit' in Liver Cancer Trial
https://www.medscape.com/viewarticle/978721

Aug 5th, 2022 - The combination of a tyrosine kinase inhibitor with an immune checkpoint inhibitor significantly improved progression-free survival in patients with hepatocellular carcinoma, shows a new study. While the combination has been shown to be beneficial...

Treatment combo shows ‘clinical benefit’ in liver cancer trial
https://www.mdedge.com/hematology-oncology/article/256782/gastrointestinal-cancer/treatment-combo-shows-clinical-benefit
Jim Kling

Aug 3rd, 2022 - The combination of a tyrosine kinase inhibitor with an immune checkpoint inhibitor significantly improved progression-free survival in patients with hepatocellular carcinoma, shows a new study. While the combination has been shown to be beneficial.

Targeted Therapy for Kidney Cancer Linked to Higher Cardiac Risk
https://www.medscape.com/viewarticle/978519

Aug 3rd, 2022 - New research offers more evidence linking targeted therapies for patients with advanced renal cell carcinoma to higher risks for major adverse cardiovascular events. Patients on targeted therapy were more likely to develop conditions such as heart...

Immuno-oncology combos show promise in renal cell cancer
https://www.mdedge.com/hematology-oncology/article/256591/renal-cell-carcinoma/immuno-oncology-combos-show-promise-renal
Randy Dotinga

Jul 28th, 2022 - In advanced renal cell carcinoma, four out of five immuno-oncology drug-based combination treatments are showing impressive results in trials, a new review finds. Based on initial data, all appear to show advantages over the standard first-line tr.

Targeted therapy for renal cell cancer linked to higher cardiac risk
https://www.mdedge.com/hematology-oncology/article/256586/renal-cell-carcinoma/targeted-therapy-renal-cell-cancer-linked
Randy Dotinga

Jul 28th, 2022 - New research offers more evidence linking targeted therapies for patients with advanced renal cell carcinoma to higher risks for major adverse cardiovascular events. Patients on targeted therapy were more likely to develop conditions such as heart.

see more →

Patient Education  4 results see all →